Genentech Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GENENTECH, and when can generic versions of GENENTECH drugs launch?
GENENTECH has nine approved drugs.
There are fifty-six US patents protecting GENENTECH drugs.
There are eight hundred and forty-three patent family members on GENENTECH drugs in fifty-three countries and eighty-six supplementary protection certificates in nineteen countries.
Summary for Genentech
| International Patents: | 843 |
| US Patents: | 56 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 9 |
| Patent Litigation for Genentech: | See patent lawsuits for Genentech |
| PTAB Cases with Genentech as patent owner: | See PTAB cases with Genentech as patent owner |
Drugs and US Patents for Genentech
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | DISCN | Yes | No | 7,635,707 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Genentech Inc | ROZLYTREK | entrectinib | CAPSULE;ORAL | 212725-002 | Aug 15, 2019 | RX | Yes | Yes | 9,029,356 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Genentech Inc | ROZLYTREK | entrectinib | CAPSULE;ORAL | 212725-002 | Aug 15, 2019 | RX | Yes | Yes | 9,085,565 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | AB | RX | Yes | No | 8,383,150 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Genentech Inc | ROZLYTREK | entrectinib | CAPSULE;ORAL | 212725-001 | Aug 15, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | AB | RX | Yes | Yes | 8,754,109 | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Genentech
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | 9,561,217 | ⤷ Try a Trial |
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | 9,561,217 | ⤷ Try a Trial |
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | 9,561,217 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GENENTECH drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 267 mg, 534 mg and 801 mg | ➤ Subscribe | 2018-10-15 |
International Patents for Genentech Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Argentina | 121624 | ⤷ Try a Trial |
| Poland | 2620436 | ⤷ Try a Trial |
| Turkey | 201808501 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2011069094 | ⤷ Try a Trial |
| South Korea | 20200065025 | ⤷ Try a Trial |
| Australia | 2015261046 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Genentech Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3143025 | CA 2021 00037 | Denmark | ⤷ Try a Trial | PRODUCT NAME: RISDIPLAM ELLER FARMACEUTISK ACCEPTABLE SALTE HERAF; REG. NO/DATE: EU/1/21/1531 20210329 |
| 3107541 | 21/2021 | Austria | ⤷ Try a Trial | PRODUCT NAME: ENTRECTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/20/1460 (MITTEILUNG) 20200803 |
| 2620436 | C02620436/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: BALOXAVIRUM MARBOXILUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67426 21.02.2020 |
| 3143025 | 2021C/537 | Belgium | ⤷ Try a Trial | PRODUCT NAME: RISDIPLAM OF FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1531 20210329 |
| 1934174 | 16C0021 | France | ⤷ Try a Trial | PRODUCT NAME: COBIMETINIB,OPTIONNELLEMENT SOUS TOUTE FORME PROTEGEE PAR LE BREVET DE BASE,NOTAMMENT SES SELS ET SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES,EN PARTICULIER L'HEMIFUMARATE DE COBIMETINIB; REGISTRATION NO/DATE: EU/1/15/1048 20151124 |
| 1789390 | C01789390/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: VISMODEGIB; REGISTRATION NO/DATE: SWISSMEDIC 62497 30.05.2013 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
